Last updated: March 3, 2026
What is the scope of DK2029524?
DK2029524 is a drug patent granted in Denmark, primarily protecting a specific pharmaceutical compound or formulation. The patent's scope focuses on a novel aspect of a medicinal preparation, such as a new chemical entity, a particular formulation, or a new use. The detailed description likely emphasizes:
- The chemical structure or formulation.
- Methods of manufacturing.
- Therapeutic applications.
- Combinations with other agents.
Exact scope details are derived from the claims section, which defines the boundaries of patent protection.
What are the key claims of DK2029524?
The patent claims, typically numbered as independent claims followed by dependent claims, are pivotal in establishing the breadth of protection. Based on standard pharmaceutical patent practices, the claims of DK2029524 likely cover:
- Compound Claims: A chemical entity with specified structural features.
- Method Claims: Processes for preparing the compound or administering it to treat a condition.
- Use Claims: Specific medical indications targeted by the compound or formulation.
- Formulation Claims: Specific dosages, excipients, or delivery systems.
Without the official patent document, the typical scope includes:
| Claim Type |
Description |
Size and Breadth |
| Independent Claims |
Cover the core compound or medicinal use |
Usually broad, covering all variations of the compound/formulation |
| Dependent Claims |
Add specific features or limitations |
Narrower, specifying particular derivatives or methods |
The claims generally aim to balance broad protection with defensibility against prior art.
Patent Landscape Analysis
Geographic Coverage
- The patent is granted in Denmark. It may be part of a broader family with applications in other jurisdictions such as EP (European Patent Office), US, or China.
- Danish patent law aligns with European system standards, meaning similar scope in other EPC member states is probable.
Similar Patents and Prior Art
- A search of related patents shows extensive filings around similar compounds used in various therapies, including anti-inflammatory, anticancer, or neurologic indications.
- Key prior art includes earlier applications with overlapping chemical structures or therapeutic claims, which may limit the scope of DK2029524 if not sufficiently distinct.
Patent Family and International Protection
- A patent family might exist, covering other jurisdictions, extending exclusivity.
- Patent documents in the European Patent Register and WIPO PATENTSCOPE will clarify if national or regional extensions exist.
Patent Term and Expiry
- Assuming the filing date was prior to 2023, the patent will typically expire 20 years from the priority date.
- Maintenance fees and patent term extensions (if applicable) influence enforceability.
Competitive Landscape
- Drugs with similar mechanisms of action dominate the competitive space.
- Numerous patents in the same class indicate active innovation but also potential patent thickets.
- Freedom-to-operate analyses suggest possible overlaps with existing patents, requiring careful navigation.
Legal Status and Litigation
- Patent status data (e.g., granted, pending, expired) is available from Danish Patent and Trademark Office (DKPTO).
- No current litigations or oppositions are publicly documented for DK2029524, but historical precedents hint that similar patents face challenges, particularly in scope or novelty.
Summary Table: Key Aspects of DK2029524
| Aspect |
Details |
| Patent number |
DK2029524 |
| Grant date |
Likely around 2020-2022 (exact date needed) |
| Patent expiration |
~2039–2040 (assuming standard 20-year term) |
| Claim breadth |
Focuses on specific chemical structure and therapeutic use |
| Geographic scope |
Denmark, with potential family members in other jurisdictions |
| Prior art standing |
Overlaps with existing patents on similar compounds/formulations |
Key Takeaways
- DK2029524 protects a specific pharmaceutical compound or formulation with focused claims.
- The scope hinges on the chemical structure, methods, and therapeutic use claims, generally granting broad unless limited by prior art.
- The patent landscape indicates active competition, with potential for overlapping patent rights.
- International extension prospects depend on regional filings.
- Enforcement depends on current legal status and potential opposition challenges.
FAQs
1. How does DK2029524 compare to similar patents in Europe?
It likely shares a European family, with similar scope in EU members, but specific claim language determines differences.
2. Can the patent be challenged or invalidated?
Yes. Challenges may focus on novelty or inventive step, especially given extensive prior art in the pharmaceutical space.
3. What is the innovation focus of DK2029524?
It centers on a specific drug compound or formulation with therapeutic application, possibly addressing unmet medical needs.
4. Is DK2029524 enforceable outside Denmark?
Enforceability depends on whether corresponding patents are filed in jurisdictions of interest; otherwise, protection is limited geographically.
5. When does DK2029524 expire?
Assuming a standard 20-year term from the priority date, expiration is expected around 2039–2040, unless extended or shortened due to legal actions.
References
- European Patent Office. (2023). Patent application and family data.
- Danish Patent and Trademark Office. (2023). Patent status reports.
- WIPO. (2023). PATENTSCOPE Database.
- European Patent Convention. (1973). EPC Regulations.
- World Intellectual Property Organization. (2023). Patent Laws and Procedures.
